HRMY — Harmony Biosciences Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802665 ·
Last close
$33.01
Market Cap
$1.94B
52W High
$43.49
52W Low
$25.90
ADV30
1,094,091
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 268,917,000 | 188,231,000 | 54,197,000 | 48,196,000 | 1,478,245,000 | 647,099,000 | 406,013,000 |
| Jun 2026 | 261,280,000 | 198,082,000 | 89,316,000 | 75,431,000 | 1,373,084,000 | 549,769,000 | 373,841,000 |
| Mar 2026 | 215,387,000 | 170,875,000 | 37,291,000 | 32,488,000 | 1,271,824,000 | 589,398,000 | 361,475,000 |
| Dec 2025 | 243,776,000 | 175,231,000 | 38,557,000 | 22,486,000 | 1,271,631,000 | 752,502,000 | 401,413,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$323,036,000
Investing CF
$-325,105,000
Financing CF
$2,169,000
CapEx
$-310,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$3.02
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$317,018,000
Inventory
$5,871,000
Receivables
$127,739,000
ST Investments
$124,039,000
EBIT TTM
$245,871,000
Pretax Income TTM
$232,961,000
Interest Exp TTM
$12,910,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$989,360,000
EBITDA
$244,696,992
Free Cash Flow
$191,779,872
Enterprise Value
$1,328,101,120
Total Cash
$771,137,984
Total Debt
$154,914,000
Shares Out
58,723,199
Trailing EPS
$3.02
Book Value
$18.26
ROE
18.7%
ROA
10.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 868,453,000 | 208,469,000 | 158,687,000 | 1,271,631,000 | 401,413,000 | 870,218,000 | 348,199,000 |
| Dec 2024 | 714,734,000 | 190,826,000 | 145,493,000 | 999,200,000 | 340,045,000 | 659,155,000 | 219,821,000 |
| Dec 2023 | 582,022,000 | 192,030,000 | 128,853,000 | 811,448,000 | 344,456,000 | 466,992,000 | 219,387,000 |
| Dec 2022 | 437,855,000 | 120,186,000 | 181,468,000 | 673,870,000 | 271,032,000 | 402,838,000 | 144,466,000 |
TTM Snapshot
Revenues TTM
$959,898,000
NetIncome TTM
$181,270,000
OpCashFlow TTM
—
Assets (Latest)
$1,373,084,000
Forward EPS
$7.00
Max Pain — expiry 2026-12-18
max pain strike: $37.50 · spot: $33.11 · call oi: 2,434 · put oi: 12,539
Expected Move to 2026-12-18:
±$4.15
(12.53%) —
implied range
$28.96 –
$37.26
· ATM straddle on $32.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $1.93B | $13.51 | — |
| SEPN | Septerna, Inc. | $1.90B | $40.02 | — |
| VERA | Vera Therapeutics, Inc. | $1.89B | $26.20 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.88B | $27.75 | — |
| BHVN | Biohaven Ltd. | $2.00B | $13.24 | — |
News headlines (Yahoo Finance, 1h cache)
Harmony Biosciences (HRMY) Stock May Be Undervalued On Earnings Power
2026-11-07 04:25 · Yahoo
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
2026-11-05 18:04 · Yahoo
Harmony Biosciences Holdings, Inc. Q3 2026 Earnings Call Summary
2026-11-04 22:30 · Yahoo
Harmony Biosciences (HRMY) Q3 2026 Earnings Call Transcript
2026-11-04 19:45 · Yahoo
Harmony Biosciences Q3 Earnings Call Highlights
2026-11-04 18:14 · Yahoo
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
2026-11-04 12:55 · Yahoo
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
2026-10-28 13:00 · Yahoo
HRMY or ARGX: Which Is the Better Value Stock Right Now?
2026-10-22 14:40 · Yahoo
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
2026-10-22 12:40 · Yahoo
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
2026-10-20 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.